A new migraine medicine called telcagepant was found safe and effective at treating migraines in a new comparative study with the migraine drug Zomig, and it did so without causing some of the common side effects of current triptan migraine drugs. In a study conducted by drugmaker Merck, researchers found that telcagepant and Zomig were similar in their effectiveness, both of which outperformed a placebo. But telcagepant works differently than triptans such as Zomig, which makes it less likely...